Membranous Nephropathy – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of MN for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

DRG Epidemiology’s MN forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MN over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following MN patient populations:

  • Diagnosed incidence of MN.
  • Diagnosed prevalence of MN.

Table of contents

  • Membranous Nephropathy - Epidemiology - Mature Markets
    • Introduction
      • Key Updates
      • Key Findings
      • Diagnosed Incidence of Membranous Nephropathy per Year per 1,000,000 People of All Ages in 2020 and 2040
      • Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Cases of Membranous Nephropathy over the Next 20 Years
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases of Membranous Nephropathy
      • Diagnosed Lifetime Prevalent Cases of Membranous Nephropathy
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Membranous Nephropathy
        • Studies Excluded from the Analysis of Membranous Nephropathy
      • Risk/Protective Factors
        • Risk/Protective Factors for Membranous Nephropathy
      • Bibliography

Login to access report

launch Related Market Assessment Reports